https://eu-response.eu/launch-of-the-eu-response-project/2026-04-03T10:20:33+02:00https://eu-response.eu/discovery-trial-in-practice/2026-06-07T21:49:38+02:00https://eu-response.eu/press-release-inserm-and-astrazeneca-join-forces-to-test-the-efficacy-of-monoclonal-antibody-combination-azd7442-on-covid-19-in-the-european-discovery-trial/2026-04-03T10:20:33+02:00https://eu-response.eu/press-release-inserm-and-astrazeneca-join-forces-to-test-the-efficacy-of-monoclonal-antibody-combination-azd7442-on-covid-19-in-the-european-discovery-trial-2/2026-04-03T10:20:33+02:00https://eu-response.eu/launch-of-european-covid-19-trials-coordination-module-website/2026-04-03T10:20:33+02:00https://eu-response.eu/remdesivir-ineffective-in-patients-hospitalized-with-covid-19-and-the-discovery-trial-continues-with-a-new-antiviral/2026-04-03T10:20:33+02:00https://eu-response.eu/bergenbio-and-oslo-university-hospital-announce-the-axl-inhibitor-bemcentinib-will-be-studied-in-the-eu-funded-eu-solidact-trial-in-hospitalised-covid-19-patients/2026-04-03T10:20:33+02:00https://eu-response.eu/remdesivir-has-a-significant-antiviral-activity-reducing-the-amount-of-viral-particles-released-by-infected-cells/2026-04-03T10:20:33+02:00https://eu-response.eu/remdesivir-has-a-significant-antiviral-activity-reducing-the-amount-of-viral-particles-released-by-infected-cells-2/2026-04-03T10:20:33+02:00https://eu-response.eu/eu-solidact-publishes-resuts-on-baricitinib-as-a-treatment-for-hospitalized-covid-19-patients/2026-04-03T10:20:33+02:00https://eu-response.eu/eu-response-first-face-to-face-consortium-meeting/2026-04-03T10:20:33+02:00https://eu-response.eu/discovery-publishes-an-article-on-management-of-pharmacovigilance-during-the-covid-19-pandemic-crisis/2026-06-12T14:58:13+02:00https://eu-response.eu/discovery-publishes-an-article-on-quality-control-in-the-context-of-the-sars-cov-2-epidemic/2026-06-12T14:58:13+02:00https://eu-response.eu/eu-response-supports-a-global-meta-analysis-on-jak-inhibitors-in-hospitalized-covid-19-patients/2026-06-12T14:58:13+02:00https://eu-response.eu/discovery-publishes-an-article-on-association-between-sars-cov-2-viral-kinetics-and-clinical-score-evolution-in-hospitalized-patients/2026-06-12T14:58:13+02:00https://eu-response.eu/cardiac-adverse-events-and-remdesivir-in-hospitalized-patients-with-coronavirus-disease-2019-covid-19-a-post-hoc-safety-analysis-of-the-randomized-discovery-trial/2026-06-12T14:58:13+02:00https://eu-response.eu/discovery-publishes-a-letter-on-tixagevimab-cilgavimab-azd7442-for-the-treatment-of-patients-hospitalized-with-covid-19-discovery-a-phase-3-randomized-double-blind-placebo-controlled-trial/2026-06-12T14:58:13+02:00https://eu-response.eu/coordination-of-covid-19-platform-trials-in-europe/2026-06-12T14:58:13+02:00https://eu-response.eu/eu-response-second-face-to-face-consortium-meeting/2026-06-12T14:58:13+02:00https://eu-response.eu/survey-databases-for-target-trial-emulations/2026-06-12T14:58:12+02:00https://eu-response.eu/sst2-is-a-key-outcome-biomarker-in-covid-19-insights-from-discovery-randomized-trial/2026-06-12T14:58:12+02:00https://eu-response.eu/eu-response-second-face-to-face-consortium-meeting-2/2026-06-12T14:58:12+02:00https://eu-response.eu/eu-response-at-eccmid-2025/2026-06-12T14:58:12+02:00